Weekly Pharma & Life Science News Round-Up: 18th – 22nd July

A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 18^th-22^nd July.

Astorg completes acquisition of OPEN Health from Amulet Capital Partners

Astorg and Amulet Capital Partners announces that they have completed the previously announced transaction whereby Astorg has acquired OPEN Health, a leading global provider of scientific communications and market access services to the pharmaceutical industry.

APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights

APONTIS PHARMA has concluded a further development partnership with Midas Pharma as part of its growth strategy.

Oxford Science enterprises raises £250 million

Oxford Science Enterprises, the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announces it has raised a further £250 million in funding.

Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, announces that it has signed a strategic R&D collaboration and license agreement with Nestlé Health Science.

Haleon launches with purpose to deliver better everyday health with humanity

Haleon launches as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity.

Essential Pharma makes strong progress in its ESG performance and now exceeds sector benchmarks

Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces strong year-on-year progress in its ESG performance.

La Dose Tech launches Healthtech Explore, Europe’s first comprehensive health tech mapping

La Dose Tech, a networking community and media outlet that brings together innovators and thought leaders at the intersection of healthcare and technology, announces the launch of its latest feature, Healthtech Explore – a search engine that lists 400+ companies in the health tech sector.

AbbVie and iSTAR Medical announce strategic alliance for the treatment of glaucoma

AbbVie and iSTAR Medical SA, announce a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject^® device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.

PharmaSGP successfully secures financing of up to €160 million

Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved record sales valued at € 65.3 million in the past financial year.

Clinical Outcomes Solutions and Genesis Research announce innovative partnership

Established in 2013, COS is a global leader in delivering innovative science to capture and communicate the patient voice, in order to provide actionable evidence in clinical drug development through qualitative and quantitative research, with a focus on Clinical Outcomes Assessments.

Celegence acquires Qdossier to bolster its regulatory consultancy services and solutions for the pharmaceutical industry

Celegence has announced the acquisition of Qdossier, a supplier of end-to-end services to support document and dossier lifescyle management for pharmaceutical products.

Vertex and Verve Therapeutics establish collaboration to discover and develop an in vivo gene editing program for liver disease

Vertex Pharmaceuticals Incorporated and Verve Therapeutics, Inc. announce an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene editing program for a single undisclosed liver disease.

Eckert & Ziegler affiliate receives further NIAID funding for clinical development

Myelo Therapeutics has announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their contract to advance the development of the new chemical entity Myelo001 to mitigate the acute radiation syndrome.

Almirall launches new call to find innovative therapies for skin diseases

Almirall, S.A., a global biopharmaceutical company focused on skin health, today launched its 7^th call through AlmirallShare, its open innovation platform, for proposals to establish collaborations in dermatological research.

Owkin, the Francis Crick Institute and The Royal Marsden NHS Foundation Trust to use AI to research kidney cancer evolution

Owkin is partnering with scientists from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust in London to use artificial intelligence (AI) to research how the evolution of a kidney cancer tumour is linked to differences in its microscopic structure.